CD44 and breast neoplasm: MK-0752 is a gamma-secretase inhibitor, already with a phase II clinical trial completed, that showed promising results targeting BCSCs, since a decrease in CD44+CD24- population, as well as decreased mammosphere forming efficiency, was observed in samples from breast tumour serial biopsies [32,108].